A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Public ClinicalTrials.gov record NCT06655324. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Study identification
- NCT ID
- NCT06655324
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 250 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years to 30 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2024 (Actual)
- Primary completion
- Jul 17, 2028 (Estimated)
- Completion
- Jul 17, 2028 (Estimated)
- Last update posted
- Sep 17, 2026
2024 – 2028
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Clinical Trials Medical Group managed by PAREXEL ( Site 0011) | Glendale | California | 91206 | Completed |
| QPS-MRA, LLC ( Site 0012) | South Miami | Florida | 33143 | Active, not recruiting |
| Alliance for Multispecialty Research, LLC ( Site 0008) | Kansas City | Missouri | 64114 | Recruiting |
| Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016) | Springfield | Missouri | 65802 | Recruiting |
| Velocity Clinical Research Lincoln ( Site 0004) | Lincoln | Nebraska | 68510 | Recruiting |
| Velocity Clinical Research, Omaha ( Site 0005) | Omaha | Nebraska | 68134 | Recruiting |
| Remington-Davis, Inc. ( Site 0017) | Columbus | Ohio | 43215 | Recruiting |
| Lynn Health Science Institute ( Site 0010) | Oklahoma City | Oklahoma | 73112 | Recruiting |
| Alliance for Multispecialty Research, LLC ( Site 0009) | Knoxville | Tennessee | 37909 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06655324, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 17, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06655324 live on ClinicalTrials.gov.